CYDY - Enrollment underway in CytoDyn's long-haulers COVID-19 trial

CytoDyn (CYDY) has enrolled and dosed 20 patients in the first 10 days of its Phase 2 trial for COVID-19 long-haulers symptoms. The trial is designed to enroll 50 patients.The trial will evaluate the efficacy and safety of leronlimab in patients with prolonged COVID-19 symptoms (long-haulers). Each patient will receive eight weekly doses followed by four weeks of safety evaluation.The endpoint measure will be at Day 56 with the trial data expected by mid-summer of 2021.Recently, the company released data from CD12 Phase 3 trial in COVID-19 which failed to meet endpoints.

For further details see:

Enrollment underway in CytoDyn’s long-haulers COVID-19 trial